Abstract
Background
The aim of the study was to evaluate high-sensitivity C-reactive protein (hs-CRP) and fibrinogen in non-obese normoinsulinemic adolescent girls with polycystic ovary syndrome (PCOS) and their relationship with anthropometric and lipid parameters.
Methods
The study comprised a total of 26 adolescent girls newly diagnosed with PCOS and 12 healthy controls with regular ovulatory menstrual cycles. The concentration of hs-CRP, fibrinogen, anthropometric measurements, and biochemical and hormonal testing were assessed.
Results
PCOS adolescent girls had significantly higher levels of hs-CRP and fibrinogen compared to healthy controls. In univariate regression analysis, statistically significant associations of hs-CRP and fibrinogen levels of PCOS patients have been shown with body mass index (BMI), waist circumference (WC), hip circumference (HC) and low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratio, while hs-CRP levels were also associated with cholesterol and LDL. In the multivariate regression model, we found that hs-CRP levels were predicted by BMI (β=0.541, p<0.001) and LDL (β=0.507, p=0.014), while fibrinogen levels were predicted by BMI (β=0.449, p=0.004).
Conclusions
We have shown an association of proinflammatory indices hs-CRP and fibrinogen with anthropometric and lipid parameters of adolescent women with PCOS. The inflammatory markers might be useful in monitoring normal-weight adolescent women with PCOS in an effort to timely prevent unfavorable changes in body mass and lipid profile.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was funded by the Serbian Ministry of Education, Science and Technological Development (grant numbers 175052, 175032 and 41009).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Conflict of interest statement: The authors have declared no conflicts of interest.
References
1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–11.10.1210/jcem.84.11.6148Search in Google Scholar PubMed
2. Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Front Horm Res 2013;40:22–7.10.1159/000341679Search in Google Scholar PubMed
3. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes 2007;31:S8–13.10.1038/sj.ijo.0803730Search in Google Scholar
4. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607–13.10.1016/S0002-9343(01)00948-2Search in Google Scholar PubMed
5. Nezi M, Christopoulos P, Paltoglou G, Gryparis A, Bakoulas V, et al. Focus on BMI and subclinical hypothyroidism in adolescent girls first examined for amenorrhea or oligomenorrhea. The emerging role of polycystic ovary syndrome. J Pediatr Endocrinol Metab 2016;29:693–702.10.1515/jpem-2015-0312Search in Google Scholar PubMed
6. Macut D, Bačević M, Božić-Antić I, Bjekić-Macut J, Čivčić M, et al. Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015;2015:812610.10.1155/2015/812610Search in Google Scholar PubMed PubMed Central
7. Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013;40:51–63.10.1159/000341683Search in Google Scholar PubMed
8. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012;18:112–26.10.1093/humupd/dmr046Search in Google Scholar PubMed PubMed Central
9. Libby P. Inflammation and atherosclerosis. Circulation 2002;105:1135–43.10.1161/hc0902.104353Search in Google Scholar PubMed
10. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165–97.10.1146/annurev.immunol.021908.132620Search in Google Scholar PubMed PubMed Central
11. Odegaard AO, Jacobs DR, Sanchez OA, Goff DC, Reiner AP, et al. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol 2016;15:51.10.1186/s12933-016-0369-6Search in Google Scholar PubMed PubMed Central
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836–43.10.1056/NEJM200003233421202Search in Google Scholar PubMed
13. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335:30–41.10.1016/j.mce.2010.08.002Search in Google Scholar PubMed
14. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102:1634–8.10.1161/01.CIR.102.14.1634Search in Google Scholar PubMed
15. Wang J, Tan G-J, Han L-N, Bai Y-Y, He M, et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol 2017;14:135–50.Search in Google Scholar PubMed
16. Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87:3287–90.10.1210/jcem.87.7.8634Search in Google Scholar PubMed
17. Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, et al. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011;96:1068–76.10.1210/jc.2010-2279Search in Google Scholar PubMed
18. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357–63.10.1210/jc.2005-2430Search in Google Scholar PubMed
19. Christensen SB, Black MH, Smith N, Martinez MM, Jacobsen SJ, et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril 2013;100:470–7.10.1016/j.fertnstert.2013.04.001Search in Google Scholar PubMed PubMed Central
20. Hashemipour M, Faghihimani S, Zolfaghary B, Hovsepian S, Ahmadi F, et al. Prevalence of polycystic ovary syndrome in girls aged 14–18 years in Isfahan, Iran. Horm Res 2004;62:278–82.10.1159/000081842Search in Google Scholar PubMed
21. Macut D, Micić D, Cvijović G, Sumarac M, Kendereski A, et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001;14(Suppl 5):1353–9; discussion 1365.Search in Google Scholar
22. Bajuk Studen K, Jensterle Sever M, Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Front Horm Res 2013;40:64–82.10.1159/000341838Search in Google Scholar PubMed
23. Macut D, Antić IB, Bjekić-Macut J. Cardiovascular risk factors and events in women with androgen excess. J Endocrinol Invest 2015;38:295–301.10.1007/s40618-014-0215-1Search in Google Scholar PubMed
24. Hughan KS, Tfayli H, Warren-Ulanch JG, Barinas-Mitchell E, Arslanian SA. Early biomarkers of subclinical atherosclerosis in obese adolescent girls with polycystic ovary syndrome. J Pediatr 2016;168:104–11.e1.10.1016/j.jpeds.2015.09.082Search in Google Scholar PubMed PubMed Central
25. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.10.1016/j.fertnstert.2003.10.004Search in Google Scholar PubMed
26. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010;203:201.e1–5.10.1016/j.ajog.2010.03.008Search in Google Scholar PubMed
27. Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 2015;83:376–89.10.1159/000375530Search in Google Scholar PubMed
28. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002;57:755–67.10.1097/00006254-200211000-00022Search in Google Scholar PubMed
29. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7.10.1210/jcem-21-11-1440Search in Google Scholar PubMed
30. Balen AH, Laven JS, Tan S-L, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505–14.10.1093/humupd/dmg044Search in Google Scholar PubMed
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.10.1007/BF00280883Search in Google Scholar PubMed
32. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70.10.2337/diacare.22.9.1462Search in Google Scholar PubMed
33. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, et al. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90:6014–21.10.1210/jc.2005-1002Search in Google Scholar PubMed
34. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998;69:236–41.10.1016/S0015-0282(97)00486-XSearch in Google Scholar PubMed
35. Mohamadin A, Habib F, Al-Saggaf A. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. Ann Saudi Med 2010;30:278.10.4103/0256-4947.65255Search in Google Scholar PubMed PubMed Central
36. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986–91.10.1161/01.ATV.19.8.1986Search in Google Scholar PubMed
37. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061–5.10.1136/bmj.312.7038.1061Search in Google Scholar PubMed PubMed Central
38. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764–72.10.1161/01.RES.0000146094.59640.13Search in Google Scholar PubMed
39. Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract 2017;130:163–70.10.1016/j.diabres.2017.06.011Search in Google Scholar PubMed
40. Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961–7.10.1161/01.ATV.21.6.961Search in Google Scholar PubMed
41. Klisic AN, Vasiljevic ND, Simic TP, Djukic TI, Maksimovic MZ, et al. Association between C-reactive protein, anthropometric and lipid parameters among healthy normal weight and overweight postmenopausal women in Montenegro. Lab Med 2014;45:12–6.10.1309/LMI6I2RN7AMPEUULSearch in Google Scholar PubMed
42. Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents: current and future treatment options. Paediatr Drugs 2006;8:311–8.10.2165/00148581-200608050-00004Search in Google Scholar PubMed
43. Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164:53–60.10.1530/EJE-10-0692Search in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
